Michael Andreeff, MD, PhD, discusses the rationale for investigating uproleselan plus venetoclax and azacitidine in patients with acute myeloid leukemia.
Michael Andreeff, MD, PhD
Advertisement
Articles by Michael Andreeff, MD, PhD
Michael Andreeff, MD, PhD, chair of genetics, professor of medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in acute myeloid leukemia.
Advertisement
Latest Updated Articles
Dr. Andreeff Discusses Promise of Venetoclax in AMLDecember 21st 2018
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
2
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
3
Dr Morgans on the Design of the ARACOG Trial in Prostate Cancer
4
Introduction and Frontline Treatment Options for EGFR-Mutated NSCLC
5